Anavex Highlights Role of Sigma-1 Brain Receptor in Alzheimer’s Development

Anavex Highlights Role of Sigma-1 Brain Receptor in Alzheimer’s Development
Anavex Life Sciences has published a study demonstrating the sigma-1 receptor’s role in Alzheimer’s disease. The data contained in it supports the New York-based company’s development of compounds stimulating this receptor as a way of treating the illness. The study, “Sigma-1 Receptor Agonists Induce Oxidative Stress in Mitochondria and Enhance Complex I Activity in Physiological

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

5 comments

  1. Jared says:

    They will be launching a phase 2/3, which is expected to be the final trial before submitting for FDA approval. Please correct the article.

  2. Andrew Summerville says:

    The Anavex studies have been more than encouraging to this point in time. The company is currently fine-tuning before launching the upcoming phase 2/3 clinical trial. This could be the technology that has evaded Big Pharma for decades.

Leave a Comment

Your email address will not be published. Required fields are marked *